Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYFED vs AFRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies,Off-label: used as a stimulant or for weight loss (not recommended)
Temporary relief of nasal congestion due to colds, hay fever, or other upper respiratory allergies.
500 mg orally twice daily with meals.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Hepatic metabolism via N-demethylation to active metabolite; undergoes some phase I and phase II metabolism; excreted renally.
Primarily hepatic metabolism via oxidative deamination and glucuronidation; the major enzyme involved is monoamine oxidase (MAO).
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
25-30% bound to serum albumin.
80–90% bound to serum albumin and alpha-1-acid glycoprotein.
1-2 L/kg, indicating extensive tissue distribution.
4.0–5.0 L/kg. Indicates extensive tissue distribution, with concentrations exceeding plasma levels in lung, liver, kidney, and brain.
Oral: 60-70% due to first-pass metabolism.
Oral: 40–50% (first-pass metabolism). Intranasal: 70–80% (systemic absorption variable). Intravenous: 100%.
GFR ≥60 m L/min: 500 mg twice daily. GFR 30-59: 500 mg once daily. GFR <30: 500 mg every other day.
Cr Cl 30-50 m L/min: prolong interval to every 18-24 hours; Cr Cl <30 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25%. Child-Pugh C: reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, consider dose reduction; Child-Pugh C: avoid use.
Not recommended for pediatric use; safety and efficacy not established.
Children 6-12 years: 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; maximum 1 tablet per day. Children <6 years: not recommended.
No specific dose adjustment required, but monitor renal function and adjust accordingly per renal adjustment guidelines.
Start with 1/2 tablet (pseudoephedrine 60 mg, triprolidine 1.25 mg) every 12 hours; monitor for CNS effects, anticholinergic side effects, and hypertension.
None
None.
Use with caution in hypertension, coronary artery disease, hyperthyroidism, diabetes, prostatic hypertrophy, and glaucoma. Avoid in patients with severe or uncontrolled hypertension. Prolonged use may lead to rebound congestion.
Hypertension, cardiovascular disease, hyperthyroidism, diabetes mellitus, increased intraocular pressure, prostatic hyperplasia; use caution in elderly patients; do not exceed recommended dosage.
Severe hypertension, severe coronary artery disease, concurrent use of MAO inhibitors, narrow-angle glaucoma, urinary retention, and hypersensitivity to pseudoephedrine.
Hypersensitivity to any component; concurrent use or recent use (within 14 days) of MAO inhibitors; severe hypertension or coronary artery disease.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may cause hypertensive crisis with MAOIs; do not use MYFED if you have taken an MAOI in the last 14 days. Grapefruit and grapefruit juice may increase anticholinergic effects.
Avoid excessive caffeine intake as it may increase stimulant effects. No significant food interactions known.
Category C: First trimester risk of major malformations not clearly increased; second and third trimester use associated with fetal tachycardia, premature closure of ductus arteriosus, and oligohydramnios. Avoid in third trimester.
Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsistent. Second and third trimesters: Avoid due to risk of uterine vasoconstriction and potential fetal hypoxia, especially near term. Overall, FDA Pregnancy Category C.
Excreted in breast milk; M/P ratio not established. Potential for infant irritability and sleep disturbance. Use caution; manufacturers recommend avoiding during breastfeeding.
Pseudoephedrine is excreted into breast milk in small amounts (M/P ratio approximately 2.6–3.5). Use with caution as it can reduce milk production and may cause irritability in the infant. A single dose is likely safe, but chronic use is not recommended.
No standard dose adjustment recommended for pregnancy. Increased renal clearance and volume of distribution may reduce peak concentrations; however, no evidence-based dose change is indicated. Use lowest effective dose for shortest duration.
No specific dose adjustments are established for pregnancy. However, due to increased plasma volume and renal clearance, the duration of action may be shorter. Use the lowest effective dose for the shortest duration, typically 60 mg every 4–6 hours (max 240 mg/day).
MYFED is a combination of pseudoephedrine (decongestant) and triprolidine (antihistamine). Avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Use caution in elderly due to anticholinergic effects (confusion, urinary retention). May cause CNS stimulation or sedation; assess patient's response before driving.
AFRINOL contains oxymetazoline, an imidazoline sympathomimetic with alpha-adrenergic agonist activity. It causes vasoconstriction in nasal mucosa. Limit use to 3 days to avoid rhinitis medicamentosa. Avoid in patients with narrow-angle glaucoma, severe hypertension, or MAOI use. Onset is within minutes, duration up to 12 hours.
Take MYFED exactly as directed; do not exceed recommended dose due to risk of serious side effects.,Do not use with other products containing pseudoephedrine or other decongestants.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not drive or operate machinery until you know how MYFED affects you.,Stop use and consult doctor if you experience fast, irregular heartbeat, severe dizziness, or difficulty urinating.
Do not use for more than 3 consecutive days to avoid rebound congestion.,Do not share the bottle with others to prevent infection.,Do not exceed recommended dosage; use only 2-3 sprays per nostril every 10-12 hours as directed.,Avoid using if you have high blood pressure, heart disease, or glaucoma without consulting a doctor.,Consult a doctor if symptoms persist beyond 3 days or if you experience severe side effects like headache, rapid heartbeat, or dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYFED vs AFRINOL, answered by our medical review team.
MYFED is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.. AFRINOL is a Decongestant that works by Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYFED and AFRINOL depend on the specific clinical indication. These are both Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYFED is: 500 mg orally twice daily with meals.. The standard adult dose of AFRINOL is: Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYFED and AFRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYFED is classified as Category C. Category C: First trimester risk of major malformations not clearly increased; second and third trimester use associated with fetal tachycardia, premature closure of ductus arterio. AFRINOL is classified as Category C. Afrinol (pseudoephedrine) is generally considered low risk during pregnancy. First trimester: Some studies suggest a possible association with gastroschisis, but data are inconsist. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.